Assays For Detecting Peanut Allergies
AssigneeAllerGenis LLC
InventorsRobert C. Getts, Paul Kearney
Life of this patent
Estimating the term…
Abstract
The present disclosure provides peanut peptide compositions and kits, and methods for diagnosis of peanut allergy, methods for detecting the development of clinical tolerance to peanuts, and methods for desensitizing an infant to peanut allergens.
Claims20
A method for diagnosing a peanut allergy in a subject comprising:
- contacting two peanut peptides coupled to a solid support with a biological sample obtained from the subject under conditions sufficient to permit binding of one or more allergy associated immunoglobulins (AAIs) in the biological sample to the two peanut peptides to form AAI-peptide-solid support complexes, wherein one of the two peanut peptides comprises the amino acid sequence WELQGDRRCQSQLER (SEQ ID NO:1) or an amino acid sequence comprising SEQ ID NO:1 but having one to four conservative amino acid substitutions therein, and the other of the two peanut peptides comprises the amino acid sequence DSYERDPYSPSQDPY (SEQ ID NO:2) or an amino acid sequence comprising SEQ ID NO:2 but having one to four conservative amino acid substitutions therein;
- contacting the AAI-peptide-solid support complexes with an AAI-specific labeling reagent to form labeling reagent-AAI-peptide-solid support complexes;
- and
- measuring the binding of the AAI-specific labeling reagent to each AAI-peptide-solid support complex;
- wherein when the combined binding for each peanut peptide in the AAI-peptide solid support complex to the AAI-specific labeling reagent is greater than a threshold value, the subject is allergic to peanuts, and when the combined binding for each peanut peptide in the AAI-peptide solid support complex to the AAI-specific labeling reagent is equal to or less than the threshold value, the subject is not allergic to peanuts.
A method for detecting development of clinical tolerance to peanuts in a subject that is allergic to peanuts comprising:
- contacting two peanut peptides coupled to a solid support with a biological sample obtained from the subject under conditions sufficient to permit binding of one or more allergy associated immunoglobulins (AAIs) in the biological sample to the two peanut peptides to form two AAI-peptide-solid support complexes, wherein one of the two peanut peptides comprises the amino acid sequence WELQGDRRCQSQLER (SEQ ID NO:1) or an amino acid sequence comprising SEQ ID NO:
- 1 but having one to four conservative amino acid substitutions therein, and the other of the two peanut peptides comprises the amino acid sequence DSYERDPYSPSQDPY (SEQ ID NO:2) or an amino acid sequence comprising SEQ ID NO:2 but having one to four conservative amino acid substitutions therein;
- contacting the AAI-peptide-solid support complexes with an AAI-specific labeling reagent to form labeling reagent-AAI-peptide-solid support complexes;
- measuring the binding of the AAI-specific labeling reagent to each AAI-peptide-solid support complex;
- and
- comparing the binding of the AAI-specific labeling reagent to each AAI-peptide-solid support complex to the binding of the AAI-specific labeling reagent to each AAI-peptide-solid support complex from a biological sample previously obtained from the subject;
- wherein when the combined binding for each peanut peptide in the AAI-peptide solid support complex to the AAI-specific labeling reagent is greater than or equal to the combined binding for each peanut peptide in the AAI-peptide solid support complex to the AAI-specific labeling reagent for the previously obtained biological sample, the subject has not established clinical tolerance to peanuts;
- and when the combined binding for each peanut peptide in the AAI-peptide solid support complex to the AAI-specific labeling reagent is less than the combined binding for each peanut peptide in the AAI-peptide solid support complex to the AAI-specific labeling reagent for the previously obtained biological sample, the subject has established clinical tolerance to peanuts.
A method of desensitizing an infant to two peanut allergens to induce tolerance or non-allergy to peanuts comprising administering two peanut peptides to the infant, wherein one of the two peanut peptides comprises the amino acid sequence WELQGDRRCQSQLER (SEQ ID NO:1) or an amino acid sequence comprising SEQ ID NO:1 but having one to four conservative amino acid substitutions therein, and the other of the two peanut peptides comprises the amino acid sequence DSYERDPYSPSQDPY (SEQ ID NO:2) or an amino acid sequence comprising SEQ ID NO:2 but having one to four conservative amino acid substitutions therein.
A composition consisting of a first peanut peptide comprising the amino acid sequence WELQGDRRCQSQLER (SEQ ID NO:1) or an amino acid sequence comprising SEQ ID NO:1 but having one to four conservative amino acid substitutions therein, and a second peanut peptide comprising the amino acid sequence DSYERDPYSPSQDPY (SEQ ID NO:
- 2) or an amino acid sequence comprising SEQ ID NO:2 but having one to four conservative amino acid substitutions therein.
A kit comprising:
- a solid support coupled to a first peanut peptide comprising the amino acid sequence WELQGDRRCQSQLER (SEQ ID NO:1) or an amino acid sequence comprising SEQ ID NO:
- 1 but having one to four conservative amino acid substitutions therein, and a second peanut peptide comprising the amino acid sequence DSYERDPYSPSQDPY (SEQ ID NO:2) or an amino acid sequence comprising SEQ ID NO:2 but having one to four conservative amino acid substitutions therein;
- and
- an allergy associated immunoglobulin (AAI)-specific labeling reagent.
Dependencies are inferred from the claim text.